Based on ratings from 17 stock analysts, the Insulet Corp stock price is expected to increase by 5.11% in 12 months. This is calculated by using the average 12-month stock price forecast for Insulet Corp. The lowest target is $185 and the highest is $285. Please note analyst price targets are not guaranteed and could be missed completely.
PODD is a stock in Healthcare which has been forecasted to be worth $247.64 as an average. On the higher end, the forecast price is $285 USD by Jayson Bedford from Raymond James and on the lower end PODD is forecasted to be $185 by from SVB Leerink.
These are the latest 20 analyst ratings of PODD.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Marie Thibault BTIG | Buy | $260 | Maintains | Oct 14, 2024 |
Jayson Bedford Raymond James | Outperform | $260 | Maintains | Oct 14, 2024 |
Joanne Wuensch Citigroup | Buy | $275 | Maintains | Oct 1, 2024 |
William Plovanic Canaccord Genuity | Buy | $269 | Maintains | Sep 25, 2024 |
Matt O'Brien Piper Sandler | Overweight | $285 | Maintains | Sep 17, 2024 |
Matt Miksic Barclays | Equal-Weight | $220 | Maintains | Aug 12, 2024 |
Matthew Taylor UBS | Neutral | $223 | Maintains | Aug 9, 2024 |
Marie Thibault BTIG | Buy | $250 | Maintains | Aug 9, 2024 |
William Plovanic Canaccord Genuity | Buy | $234 | Maintains | Jul 23, 2024 |
OTR Global | Mixed | Downgrade | Jun 10, 2024 | |
Issie Kirby Redburn Atlantic | Buy | $235 | Initiates | May 30, 2024 |
Matt Miksic Barclays | Equal-Weight | $200 | Maintains | May 13, 2024 |
Matthew Taylor Jefferies | Buy | $260 | Maintains | May 10, 2024 |
Jayson Bedford Raymond James | Outperform | $213 | Maintains | May 10, 2024 |
Kyle Rose Canaccord Genuity | Buy | $234 | Maintains | May 10, 2024 |
Mike Polark Wolfe Research | Outperform | $200 | Upgrade | May 7, 2024 |
Matt Miksic Barclays | Equal-Weight | $213 | Maintains | Feb 26, 2024 |
Matt O'Brien Piper Sandler | Overweight | $230 | Maintains | Feb 23, 2024 |
Robbie Marcus JP Morgan | Overweight | $225 | Maintains | Feb 23, 2024 |
Mathew Blackman Stifel | Hold | $208 | Maintains | Feb 5, 2024 |
When did it IPO
2007
Staff Count
3,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. James R. Hollingshead Ph.D.
Market Cap
$16.23B
In 2023, PODD generated $1.70B in revenue, which was a increase of 30.02% from the previous year. This can be seen as a signal that PODD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Insulet (PODD) is not expected to meet the criteria for a potential earnings beat in its upcoming report, according to key expectations outlined.
Why It Matters - Insulet's potential earnings miss could negatively impact its stock price, indicating weakness in performance and affecting investor confidence in future growth prospects.
Summary - Insulet Corporation (NASDAQ: PODD) will celebrate National Diabetes Awareness Month and World Diabetes Day in November with various activities to support diabetes management.
Why It Matters - Insulet's announcement highlights its commitment to diabetes awareness, potentially enhancing brand loyalty and market position, which can positively impact stock performance and investor sentiment.
Summary - Insulet Corporation released the Omnipod 5 App for iPhone, enabling full control of its Automated Insulin Delivery System. The app is available for free on the Apple App Store.
Why It Matters - The launch of the Omnipod 5 App enhances Insulet's product ecosystem, potentially increasing user adoption and sales, positively impacting revenue and stock performance.
Summary - PODD is expanding the market for its Omnipod 5 product and maintains strong solvency, indicating financial stability.
Why It Matters - PODD's market expansion and strong solvency suggest growth potential and stability, indicating a favorable environment for investment and future profitability.
Summary - Phibro Animal Health (PAHC) and Insulet (PODD) are two Medical - Products stocks of interest to investors. A comparison for value investment potential is suggested.
Why It Matters - The comparison between Phibro Animal Health and Insulet highlights potential investment opportunities, influencing stock selection strategies and impacting portfolio performance.
Summary - NVIDIA, Insulet, and Monolithic Power Systems are identified as top investment picks due to their high net income ratios.
Why It Matters - High net income ratios for NVIDIA, Insulet, and Monolithic Power Systems indicate strong profitability, signaling potential for growth and investment returns.